CD38 and non-Hodgkin lymphoma: SAR442257 by Sanofi targets CD38, CD3 and CD28 (54) and is currently under investigation in a phase I trial for the treatment of relapsed and refractory multiple myeloma and non-Hodgkin’s lymphoma (NCT04401020).